Xianping Lu

2.7k total citations · 1 hit paper
44 papers, 1.7k citations indexed

About

Xianping Lu is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Xianping Lu has authored 44 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 14 papers in Oncology and 5 papers in Physiology. Recurrent topics in Xianping Lu's work include Histone Deacetylase Inhibitors Research (13 papers), Protein Degradation and Inhibitors (9 papers) and Peptidase Inhibition and Analysis (7 papers). Xianping Lu is often cited by papers focused on Histone Deacetylase Inhibitors Research (13 papers), Protein Degradation and Inhibitors (9 papers) and Peptidase Inhibition and Analysis (7 papers). Xianping Lu collaborates with scholars based in China, United States and Hong Kong. Xianping Lu's co-authors include Zhiqiang Ning, Desi Pan, Zhibin Li, Haixiang Cao, Song Shan, Mei Dong, Shan Song, Magnus Pfahl, Jing-Zhong Zhu and Xinhao Wang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Xianping Lu

41 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in targeting histone deacetylase for treatment of solid tumors

2024 56 citations Ying Xu, Xin Fu et al. Journal of Hematology & Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xianping Lu China	21	1.2k	505	267	205	142	44	1.7k
K. M. Nicholson United Kingdom	4	1.1k 1.0×	380 0.8×	141 0.5×	112 0.5×	82 0.6×	6	1.5k
Allard Kaptein Netherlands	20	1.1k 0.9×	478 0.9×	455 1.7×	422 2.1×	120 0.8×	39	2.3k
Raffaella Dell’Eva Italy	17	746 0.6×	261 0.5×	146 0.5×	256 1.2×	93 0.7×	22	1.4k
Yang‐Ming Yang United States	14	814 0.7×	485 1.0×	84 0.3×	477 2.3×	60 0.4×	26	1.7k
Hudie Wei China	14	835 0.7×	550 1.1×	93 0.3×	211 1.0×	76 0.5×	31	1.5k
Jane L. Roberts United States	29	1.1k 1.0×	461 0.9×	107 0.4×	236 1.2×	41 0.3×	69	1.9k
Arun Kumar Trivedi India	24	940 0.8×	327 0.6×	58 0.2×	162 0.8×	126 0.9×	70	1.5k
Janeen H. Trembley United States	23	1.3k 1.1×	611 1.2×	133 0.5×	100 0.5×	125 0.9×	72	1.9k
M Oshimura Japan	9	945 0.8×	265 0.5×	189 0.7×	92 0.4×	126 0.9×	11	1.4k
Debra A. Tonetti United States	26	935 0.8×	662 1.3×	111 0.4×	178 0.9×	561 4.0×	57	1.7k

Countries citing papers authored by Xianping Lu

Since Specialization

Citations

This map shows the geographic impact of Xianping Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianping Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianping Lu more than expected).

Fields of papers citing papers by Xianping Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianping Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianping Lu. The network helps show where Xianping Lu may publish in the future.

Co-authorship network of co-authors of Xianping Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Xianping Lu. A scholar is included among the top collaborators of Xianping Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianping Lu. Xianping Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Xianping, Tianyu Zhang, Huixin Chen, et al.. (2025). First-principles study on the anchoring mechanisms of polysulfides by cyano/nitrogen vacancy modified g-C3N4. Journal of Energy Storage. 135. 118319–118319. 1 indexed citations

Gao, Leili, Linong Ji, Xin Yan, et al.. (2025). Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study). Diabetes Obesity and Metabolism. 27(11). 6243–6253.

Feng, Mengya, et al.. (2024). Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer. Cancer Cell International. 24(1). 416–416.

Xu, Ying, Xin Fu, Desi Pan, et al.. (2024). Advances in targeting histone deacetylase for treatment of solid tumors. Journal of Hematology & Oncology. 17(1). 37–37. 56 indexed citations breakdown →

Wang, Xiaodan, Meichen Gao, Xianping Lu, et al.. (2024). Resveratrol alleviates Mono-2-ethylhexyl phthalate-induced mitophagy, ferroptosis, and immunological dysfunction in grass carp hepatocytes by regulating the Nrf2 pathway. Journal of Environmental Management. 371. 123235–123235. 18 indexed citations

Ning, Zhiqiang, et al.. (2023). Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials. Journal of Diabetes. 16(2). e13484–e13484. 5 indexed citations

Zhou, You, Chao Fu, Yidi Kong, et al.. (2019). Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anti-Cancer Drugs. 30(9). 909–916. 11 indexed citations

Shi, Yue, Mei Dong, Xiaoting Hong, et al.. (2015). Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology. 26(8). 1766–1771. 263 indexed citations

Zhou, You, Desi Pan, Song Shan, et al.. (2014). Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomedicine & Pharmacotherapy. 68(4). 483–491. 57 indexed citations

10.

Ning, Zhiqiang, Zhibin Li, Michael Newman, et al.. (2011). Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemotherapy and Pharmacology. 69(4). 901–909. 221 indexed citations

11.

Liu, Li, Shan Song, Kun Zhang, et al.. (2008). Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up‐regulate transcription of adiponectin. Phytotherapy Research. 22(10). 1400–1403. 103 indexed citations

12.

Han, Haiyan, et al.. (2006). Down-regulation of prostate specific antigen in LNCaP cells by flavonoids from the pollen of Brassica napus L.. Phytomedicine. 14(5). 338–343. 38 indexed citations

13.

Li, Pingping, Shan Song, Zhiqiang Ning, et al.. (2006). The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. British Journal of Pharmacology. 148(5). 610–618. 58 indexed citations

14.

Liao, Chenzhong, Bing Liu, Leming Shi, Jiaju Zhou, & Xianping Lu. (2005). Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators. European Journal of Medicinal Chemistry. 40(7). 632–640. 12 indexed citations

15.

Liao, Chenzhong, Zhiqiang Ning, Weiming Hu, et al.. (2004). Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors. PubMed. 4(3). 273–299. 37 indexed citations

16.

Liao, Chenzhong, Jiaju Zhou, Leming Shi, et al.. (2004). 3D QSAR studies on peroxisome proliferator-activated receptor ? agonists using CoMFA and CoMSIA. Journal of Molecular Modeling. 10(3). 165–177. 22 indexed citations

17.

Li, Zhibin, Chenzhong Liao, Ben C.B. Ko, et al.. (2004). Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARα selective activators. Bioorganic & Medicinal Chemistry Letters. 14(13). 3507–3511. 16 indexed citations

18.

Lu, Xianping, Andrea Fanjul, Nathalie Picard, Braham Shroot, & Magnus Pfahl. (1999). A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. International Journal of Cancer. 80(2). 272–278. 34 indexed citations

19.

Yarovoi, Serge, Xianping Lu, Nathalie Picard, et al.. (1998). Selective Activation of an Apoptotic Retinoid Precursor in Macrophage Cell Lines. Journal of Biological Chemistry. 273(33). 20852–20859. 3 indexed citations

20.

Lu, Xianping, Andrea Fanjul, Nathalie Picard, et al.. (1997). Novel retinoid-related molecules as apoptosis inducers and effectve inhibitors of human lung cancer cells in vivo. Nature Medicine. 3(6). 686–690. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact